Results 171 to 180 of about 60,842 (306)

A Perspective on the Challenges and Issues in Developing Biomarkers for Human Allergic Risk Assessments [PDF]

, 2017
Godar, Dianne E., Merrill, Stephen, Mu, Ying   +2 more
core   +2 more sources

A Non‐Antigenic Randomized Polyethylene Glycol/Poly(2‐Phenyl‐2‐Oxazine)‐Based Drug Delivery Platform

Macromolecular Rapid Communications, EarlyView.
Randomized PEG (rPEG), a conceptually new PEG alternative, is combined with poly(2‐phenyl‐2‐oxazine) (PPheOzi) to establish an rPEG‐b‐PPheOzi‐b‐rPEG micellar drug delivery platform. The PPheOzi block enables high drug loadings, while competitive ELISA reveals a drastic reduction in anti‐PEG antibody affinity of rPEG in comparison to PEG.
Julian Schmidt, Anna‐Lena Ziegler, Florian T. Kaps, Laura J. Rosenberger, Matthias Bros, Holger Frey, Robert Luxenhofer   +6 more
wiley   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Food Hypersensitivity in Atopic Dermatitis During Infancy: Skin Prick Testing for Whom?

, 2017
Zeynep Şengül Emeksiz, Özlem Cavkaytar, İlknur Aksoy, Yıldız Daller, Özge Soyer   +4 more
openalex   +2 more sources

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, EarlyView.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Thirty years of glyphosate‐resistant crops and weeds: Current situation and future prospects

Pest Management Science, EarlyView.
Since 1996, when the first glyphosate‐resistant crop was commercialized and the first resistant weed was reported, resistance has expanded globally. This review analyzes emergence patterns across weed species, crops, regions, resistance mechanisms, and herbicides.
Ricardo Alcántara‐de la Cruz, Yure Marin Guidi, Mariana Ramirez‐Castillo, Fernando Storniolo Adegas, Caio Antonio Carbonari, Edivaldo Domingues Velini, Rafael De Prado, Stephen O. Duke   +7 more
wiley   +1 more source

RNA interference in crop protection: opportunities and challenges during the transition to commercialization

Pest Management Science, EarlyView.
RNA interference (RNAi) technologies, host‐induced gene silencing (HIGS) and spray‐induced gene silencing (SIGS), potentially offer sustainable crop protection. However, efficacy, costs, regulatory clarity, and socio‐environmental impacts require further evaluation for broader use.
Elisabetta Sergi, Anna Narduzzo, Alessandra Di Canito, Francesco Favaretto, Luca Nerva, Walter Chitarra, Lucia Bologna, Jacopo Bacenetti, Giuliana Maddalena, Simona Masiero, Ileana Vigentini, Gabriella De Lorenzis, Silvia Laura Toffolatti   +12 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Extrahepatic Gene Editing In Vivo Using Organic Solvent‐Free Lipid Nanoparticles

Small, EarlyView.
This article highlights a novel, organic solvent‐free lipid nanoparticle (LNP) formulation that avoids cholesterol, thereby reducing hepatic accumulation and immune activation. These BLNPs enable potent, flexible, and scalable gene delivery, supporting personalized medicine and diverse nucleic acid applications.
Michael Streiber, Na Liu, Laurianne Simon, Franziska Adermann, Vivien Bachmann, Lucas Gath, Stephanie Hoeppener, Stephanie Schubert, Oliver Werz, Vincent Lapinte, Marie Morille, Michael Bauer, Adrian T. Press, Ulrich S. Schubert, Anja Traeger   +14 more
wiley   +1 more source